ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Antibodies"

  • Abstract Number: 944 • 2017 ACR/ARHP Annual Meeting

    Long-Term Survival and Follow-up of Anti-Th/to Antibody Positive Systemic Sclerosis Patients

    Devon Charlton1, Maureen Laffoon2, Thomas A. Medsger Jr.3 and Robyn T. Domsic4, 1Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, 2Rheumatology, University of Pittsburgh Medical Center, Pittsburgh, PA, 3Department of Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA, 4Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Anti-Th/To antibody is an autoantibody associated with systemic sclerosis (SSc), occurring in 5-10% of patients. To date, only relatively small case series have described…
  • Abstract Number: 1428 • 2017 ACR/ARHP Annual Meeting

    Discovery and Characterization of JNJ-61178104, a Bispecific Antibody Against Human Tumor Necrosis Factor (TNF) Alpha and Interleukin (IL)-17A

    Fang Shen1, Jennifer F. Nemeth2, Brian Jones1, Ann Cai1, Shannon Hitchcock3, Thai Dinh2, Ravi Malaviya1 and Tatiana Ort1, 1Immunology, Janssen R&D, Spring House, PA, 2Janssen Biotech, Janssen R&D, Spring House, PA, 3Immunology, Janssen R&D, Springhouse, PA

    Background/Purpose: Tumor necrosis factor alpha (TNFa) and interleukin (IL)-17A are pleiotropic cytokines implicated in the pathogenesis of several autoimmune diseases including Rheumatoid Arthritis (RA) and…
  • Abstract Number: 1571 • 2017 ACR/ARHP Annual Meeting

    Bimekizumab Dual Inhibition of IL-17A and IL-17F Provides Evidence of IL-17F Contribution to Chronic Inflammation in Disease-Relevant Cells

    Ash Maroof1, Remi Okoye1, Tim Smallie1, Dominique Baeten2,3, Sophie Archer1, Catherine Simpson1, Meryn Griffiths1 and Stevan Shaw1, 1UCB Pharma, Slough, United Kingdom, 2UCB Pharma, Brussels, Belgium, 3University of Amsterdam, Amsterdam, Netherlands

    Background/Purpose: IL-17A and IL-17F share structural homology and have similar biologic function.1 Although the contribution of IL-17A to immune-mediated inflammatory diseases has been widely reported,1,2…
  • Abstract Number: 1666 • 2017 ACR/ARHP Annual Meeting

    Anti-Mitochondrial Autoantibodies in Systemic Lupus Erythematosus and Their Association with Disease Manifestations

    Yann Becker1, Renee Claude Loignon1, Genevieve Marcoux1, Anne-Sophie Julien2, Imene Melki1, Lihi Eder3, Eric Wagner1, Martin Pelletier1, Marie-Josee Hebert4, Clemence Belleannee1, Joyce Rauch5, Melanie Dieude4, Paul R. Fortin6 and Eric Boilard1, 1CHU de Quebec and Universite Laval, Quebec City, QC, Canada, 2CHU de Quebec - Universite Laval, Quebec City, QC, Canada, 3Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada, 4CHUM and Universite de Montreal, Montreal, QC, Canada, 5McGill University, Montreal, QC, Canada, 6Medicine, CHU de Quebec - Universite de Laval, Quebec, QC, Canada

    -          Background/Purpose: Eukaryotic cells contain organelles called mitochondria that govern energy supply and control of cell death. Whereas damaged organs or activated cells can extrude…
  • Abstract Number: 2091 • 2017 ACR/ARHP Annual Meeting

    Initial Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegsiticase) with Svp-Rapamycin Enables Sustained Reduction of Serum Uric Acid Levels By Mitigating Formation of Anti-Drug Antibodies

    Earl Sands1, Alan J. Kivitz2, Wesley DeHaan Ph.D.1, Lloyd Johnston1 and Takashi Kei Kishimoto1, 1Selecta Biosciences, Watertown, MA, 2Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA

    Background/Purpose:   Pegylated uricases are promising therapies for the treatment of severe chronic gout, particularly for the rapid resolution of tophi. However uricases are limited…
  • Abstract Number: 2535 • 2016 ACR/ARHP Annual Meeting

    Effect of Methotrexate in the Presence of Drug and the Appearance of Antibodies Against Tumour Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis

    Chamaida Plasencia-Rodriguez1, Ana Martínez2, Alejandro Villalba3, Teresa Jurado4, Eva Olariaga-Merida5, Araceli Mezcua6, Diana Peiteado3, Gema Bonilla3, Laura Nuño3, Alejandro Balsa1 and Dora Pascual-Salcedo2, 1Instituto de Investigación Hospital Universitario La Paz (IDIPAZ), Madrid, Spain, 2Immunology Unit, La Paz University Hospital-Immunology, Madrid, Spain, 3Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, 4Immunology Unit, La Paz University Hospital-IdiPaz, MADRID, Spain, 5Immunology, University Hospital La Paz, Madrid, Spain, 6Immunology Unit, La Paz University Hospital, Madrid, Spain

    Background/Purpose: Several factors influence pharmacokinetics of TNFinhibitors (TNFi). One relevant factor is the formation of anti drug- antibodies (ADA) associated with low drug levels and…
  • Abstract Number: 2682 • 2016 ACR/ARHP Annual Meeting

    How Does Primary Sjogren Syndrome Present in Biopsy-Proven Patients without Circulating Ro/La Autoantibodies? Characteristics at Diagnosis of 2073 Patients from the SjöGren Big Data Project

    Pilar Brito-Zerón1,2,3, Nihan Acar-Denizli4, Margit Zeher5, Astrid Rasmussen6, Raphaele Seror7, Elke Theander8, Xiaomei Li9, Chiara Baldini10, Jacques-Eric Gottenberg11, Debashish Danda12, Luca Quartuccio13, Roberta Priori14,15, Gabriela Hernandez-Molina16, Aike A. Kruize17, Valeria Valim18, Marika Kvarnström19, Damien Sene20, Roberto Gerli21, Sonja Praprotnik22, David A. Isenberg23, Roser Solans24, Maureen Rischmueller25, Seung-Ki Kwok26, Gunnel Nordmark27, Yasunori Suzuki28, Roberto Giacomelli29, Valerie Devauchelle-Pensec30, Michele Bombardieri31, Benedikt Hofauer32, Hendrika Bootsma33, Johan G. Brun34, Guadalupe Fraile35, Steven E. Carsons36, Tamer Gheita37, Jacques Morel38, Cristina F. Vollenweider39, Fabiola Atzeni40, Soledad Retamozo41, Ildike-Fanny Horvath5, Kathy Sivils6, Thomas Mandl42,43, Pulukool Sandhya12, Salvatore De Vita44, Jorge Sánchez-Guerrero45, Eefje van der Heijden17, Virginia Moça Trevisano46, Marie Wahren-Herlenius19, Xavier Mariette7, Manuel Ramos-Casals3,47,48 and EULAR-SS Task Force Big Data Consortium (ASSES, GEAS-SEMI, EULAR), 1Autoimmune Diseases Unit, Department of Medicine, Hospital CIMA- Sanitas, Barcelona., Bacelona, Spain, 2Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Barcelona, Spain, 3Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, 4Department of Statistics, Faculty of Science and Letters, Mimar Sinan Fine Arts University, Turkey, Istabul, Turkey, 5Division of Clinical Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary., Debrecen, Hungary, 6Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, USA, Oklahoma City, OK, 7Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, Paris, France, 8Department of Rheumatology, Malmö University Hospital, Lund University, Sweden, Malmö, Sweden, 9Department of Rheumatology and Immunology, Anhui Medical University Affiliated Provincial Hospital, China, Hefei, Anhui, China, 10Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, 11Department of Rheumatology, Strasbourg University Hospital, Université de Strasbourg, CNRS, Strasbourg, France, Strasbourg, France, 12Clinical Immunology & Rheumatology, Christian Medical College, Vellore, India, Vellore, India, 13Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, Udine, Italy, 14Rheumatology Unit, Sapienza University of Rome, Rome, Italy, 15Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, 16Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico City, Mexico, 17Department of Rheumatology & Clinical Immunology, Medical Center Utrecht, The Netherlands, Utrecht, Netherlands, 18Rheumatology, Department of Medicine, Universidade Federal do Espírito Santo, Vitória, Brazil, Vitória, Brazil, 19Department of Medicine, Solna, Unit of Experimental Rheumatology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, 20Service de Médecine Interne 2, Hôpital Lariboisière, Université Paris VII, Assistance Publique-Hôpitaux de Paris, 2, Paris, France, Paris, France, 21Clinical and Experimental Medicine, Rheumatology Unit, University of Perugia, Italy, Perugia, Italy, 22Department of Rheumatology, University Medical Centre Ljubljana, Slovenia, Ljubljana, Slovenia, 23Centre for Rheumatology Research, University College Hospital London, UK, London, United Kingdom, 24Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d'Hebron, Autonomous University of Barcelona, Spain, Barcelona, Spain, 25Department of Rheumatology, School of Medicine, The University of Western Australia, Crawley, Australia, Crawley, Australia, 26[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, 27Rheumatology, Department of Medical Sciences, Uppsala University, Sweden, Uppsala, Sweden, 28Division of Rheumatology , Kanazawa University Hospital , Kanazawa , Ishikawa , Japan, Ishikawa, Japan, 29Clinical Unit of Rheumatology, University of l'Aquila, School of Medicine, L'Aquila, Italy, L'Aquila, Italy, 30Department of Rheumatology, Brest University Hospital, Brest, France, Brest, France, 31Willian Harvey Research Institute, Centre for Experimental Medicine and Rheumatology, QMUL, UK, London, United Kingdom, 32Hals-Nasen-Ohrenklinik und Poliklinik, Technische Universität München, München, Germany, München, Germany, 33Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, The Netherlands, Groningen, Netherlands, 34Department of Clinical Science, University of Bergen. Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, Bergen, Norway, 35Department of Internal Medicine, Hospital Ramón y Cajal, Madrid, Spain, Madrid, Spain, 36Division of Rheumatology, Allergy and Immunology Winthrop-University Hospital, Stony Brook University School of Medicine, NY, USA, Mineola, NY, 37Rheumatology, Rheumatology Department, Faculty of Medicine, Cairo University, Egypt, Cairo, Egypt, 38Department of Rheumatology, Teaching hospital and University of Montpellier, France, Montpellier, France, 39Rheumatology, German Hospital, Buenos Aires, Argentina, Buenos Aires, Argentina, 40IRCCS Galeazzi Orthopedic Institute, Milan, Italy, Milan, Italy, 41Rheumatology Unit, Hospital Privado Centro Médico de Córdoba, Argentina, Córdoba, Argentina, 42Department of Clinical Sciences Malmö, Lund University, Skåne University Hospital, Rheumatology, Malmö, Sweden, Malmö, Sweden, 43Department of Rheumatology, Malmö University Hospital, Lund University, Sweden, Lund, Sweden, 44Clinic of Rheumatology, Department of Medical and Biological Sciences, University Hospital "Santa Maria della Misericordia", Udine, Italy, Udine, Italy, 45Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico, 46Federal University of São Paulo, Sao Paulo, Brazil, San Paulo, Brazil, 47Sjögren Syndrome Research Group (AGAUR), Barcelona, Spain, 48Department of Medicine, University of Barcelona, Barcelona, Spain., Barcelona, Spain

    Background/Purpose: To analyse the main characteristics of patients with primary Sjögren syndrome (SjS) with focal lymphocytic sialadenitis (FLS) unrelated to the presence of circulating anti-Ro/La…
  • Abstract Number: 591 • 2016 ACR/ARHP Annual Meeting

    Patient-Reported Outcomes for Etanercept Therapy in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment

    Louis Bessette1, Majed Khraishi2, Alan J Kivitz3, Arunan Kaliyaperumal4, Rama Grantab5, Melanie Poulin-Costello5, Maya Isaila5 and David Collier4, 1Rhumatology, Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, 2Medical Consultants of West Newfoundland, Western Memorial Hospital, Corner Brook, NF, Canada, 3Altoona Center for Clinical Research, Duncansville, PA, 4Amgen Inc., Thousand Oaks, CA, 5Amgen Canada Inc., Mississauga, ON, Canada

    Background/Purpose: When a tumor necrosis factor inhibitor (TNFi) fails in a patient with moderate to severe rheumatoid arthritis (RA), new American College of Rheumatology (ACR)…
  • Abstract Number: 2687 • 2016 ACR/ARHP Annual Meeting

    Prevalence of Abortions and Fetal Atrioventricular Block in Patients with Positive ANTI-RO and ANTI-La Antibodies

    Isabel Martinez Cordellat1, Francisco Miguel Ortiz-Sanjuán1, Jose Ivorra Cortes1, Luis Gonzalez Puig1, Inmaculada Chalmeta Verdejo1, Irene Calabuig Sais2, Elena Grau Garcia1,3, Carlos Feced Olmos1, Eztizen Labrador Sanchez1, Karla Arevalo Ruales1, Rosa Negueroles Albuixech1, Jorge Fragio Gil1, Jose Luis Valero Sanz1, Cristina Alcañiz Escandell1,3, Carmen Najera Herranz1, Gema Poveda Marin1,3 and Jose Andres Roman Ivorra1,2,3, 1Department of Rheumatology, Hospital Universitario y Politecnico La Fe, Valencia, Spain, 2Universidad Católica de Valencia, Valencia, Spain, 3IIS La Fe, Valencia, Spain

    Background/Purpose:   anti-SSA/Ro and/or anti-SSB/La antibodies and to evaluate the prevalence of abortions and neonatal mortality.   We included 162 patients with positive anti-SSA/Ro and/or…
  • Abstract Number: 613 • 2016 ACR/ARHP Annual Meeting

    Immunogenicity of Anti-TNF Therapies in Patients with Inflammatory Rheumatic Diseases and Secondary Failure: A Multicentre Study of 570 Patients

    Alejandro Balsa1, Raimon Sanmarti2, José Rosas3, Susana Gomez Castro4, Ana Cabez4, Victor Martin4 and María Montoro4, 1Rheumatology, IdiPAZ, Hospital Universitario La Paz, Madrid, Spain, 2Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, 3Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, 4Pfizer, Madrid, Spain

      Abstract   Immunogenicity of anti-TNF therapies in Patients with inflammatory rheumatic Diseases and secondary failure: a multicentre study of 570 patients.   Background/Purpose: The treatment of…
  • Abstract Number: 2826 • 2016 ACR/ARHP Annual Meeting

    Clinical Utility of Circulating Anti-N-Methyl-D-Aspartate Receptor Subunits NR2A/B Antibody for the Diagnosis of Neuropsychiatric Syndromes in Systemic Lupus Erythematosus and Sjogren’s Syndrome: An Updated Meta-Analysis

    Sen Hee Tay1, Anna-Marie Fairhurst2 and Anselm Mak1, 1Division of Rheumatology, Department of Medicine, National University Hospital, National University Health System, Singapore, Singapore, Singapore, 2Singapore Immunology Network, Agency for Science, Technology and Research, Singapore, Singapore

    Background/Purpose: Neuropsychiatric (NP) events are found in patients with rheumatic diseases, commonly in systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). The standard nomenclature and…
  • Abstract Number: 647 • 2016 ACR/ARHP Annual Meeting

    Genomic and Epigenetic Bioinformatics Demonstrate Dual TNF-α and IL17A Target Engagement By ABT-122, and Suggest Mainly TNF-α–Mediated Relative Target Contribution to Drug Response in MTX-IR Rheumatoid Arthritis Patients

    Robert W. Georgantas III1, Melanie Ruzek2, Justin Wade Davis1, Feng Hong1, Elizabeth Asque1, Kenneth Idler1, Heikki T. Mansikka1, Benoit Guerette1 and Jeffrey F. Waring1, 1AbbVie Inc., North Chicago, IL, 2Immunology Discovery, AbbVie, Worcester, MA

    Background/Purpose: ABT-122 is a dual variable domain (DVD-Ig) biologic which inhibits TNF-α and IL17A. In a 12-wk phase 2 study (NCT02141997) in MTX-IR patients (pts)…
  • Abstract Number: 2841 • 2016 ACR/ARHP Annual Meeting

    Anti-Ro52/TRIM21 Antibodies Are Associated with QT Interval Prolongation in Patients with Systemic Lupus Erythematosus

    Luis F. Perez-Garcia1, Irving Omar Estevez-Garcia1, Mariana Moreno Ramirez1, Javier Loaiza Felix1, Ricardo Marquez-Velasco2, Pedro Iturralde3, Luis H. Silveira4,5 and Luis M. Amezcua-Guerra1, 1Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, 2Immunology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, 3Cardiology - Electrophysiology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, 4Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City DF, Mexico, 5Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico

    Background/Purpose: Long QT syndrome (LQTS) is characterized by an abnormal QT corrected (QTc) interval prolongation that is associated with increased risk of sudden death. Studies…
  • Abstract Number: 650 • 2016 ACR/ARHP Annual Meeting

    ABT-122, a Tnf– and IL-17–Targeted Dual Variable Domain (DVD)–Ig™ in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results from a Phase 2 Trial

    Mark C. Genovese1, Michael Weinblatt2, Jacob A Aelion3, Heikki T. Mansikka4, Paul M. Peloso4, Kun Chen4, Yihan Li4, Ahmed A. Othman4, Amit Khatri4, Nasser S. Khan4 and Robert J. Padley4, 1Stanford University Medical Center, Palo Alto, CA, 2Brigham and Women’s Hospital, Boston, MA, 3West Tennessee Research Institute, Jackson, TN, 4AbbVie Inc., North Chicago, IL

    Background/Purpose: Tumor necrosis factor (TNF) and interleukin 17 (IL-17) appear to independently contribute to the pathophysiology of rheumatoid arthritis (RA), synergistically inducing inflammatory mediators leading…
  • Abstract Number: 2875 • 2016 ACR/ARHP Annual Meeting

    Depressed Serum IgM Levels in SLE Are Restricted to Defined Subgroups

    Caroline Grönwall1, Uta Hardt1, Iva Gunnarsson2, Gregg J. Silverman3 and Elisabet Svenungsson1, 1Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, 2Karolinska Institutet, Department of Medicine, Unit of Rheumatology, Stockholm, Sweden, 3Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY

    Background/Purpose: Natural IgM autoantibodies have been proposed to have protective properties, and decreased levels of IgM to phosphorylcholine (PC) in SLE are associated with higher…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 9
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology